Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025

# Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2025 (RESULT Act)

**Note:** Since the full text of this bill is not publicly available or was not provided, the following summary is based on the bill's title, context, and common features of similarly named legislation that has been introduced in recent congressional sessions.

## Summary

This bill would likely create a streamlined pathway for the U.S. Food and Drug Administration (FDA) to approve drugs, biological products, or medical devices that have already been approved by trusted regulatory agencies in other countries, such as those in the United Kingdom, European Union, Canada, Japan, Israel, or Australia. The goal is to make lifesaving treatments available to American patients more quickly by recognizing the safety and effectiveness reviews already conducted by these foreign agencies, rather than requiring the FDA to start its review process entirely from scratch.

Under this type of legislation, the FDA would still maintain oversight but could use the approval decisions of recognized foreign regulators as a basis for granting faster approval in the United States. This would primarily affect patients who are waiting for access to medications or treatments that are already legally available in other developed countries but have not yet gone through the full FDA approval process. It could also affect pharmaceutical and medical device companies by reducing the time and cost of bringing products to the U.S. market.

The bill has been introduced in the Senate and referred to the Committee on Health, Education, Labor, and Pensions, which is the committee that handles healthcare policy. It has not yet received a hearing or vote. Supporters of this approach generally argue it would speed up patient access to needed treatments, while those who raise concerns typically focus on ensuring that the FDA's safety standards are not weakened in the process.